<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4359">
  <stage>Registered</stage>
  <submitdate>24/03/2014</submitdate>
  <approvaldate>24/03/2014</approvaldate>
  <nctid>NCT02097485</nctid>
  <trial_identification>
    <studytitle>Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation</studytitle>
    <scientifictitle>A Randomised, Double-Blind, Vehicle-Controlled Study of Ovicidal Efficacy and Safety of Abametapir 0.74% Administered for the Treatment of Head Lice Infestation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Ha03-008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Head Lice Infestation</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Abametapir Lotion 0.74% w/w
Treatment: drugs - Vehicle Lotion

Active Comparator: Abametapir Lotion 0.74% w/w - Topically administered to hair and scalp for 10 minutes application.

Placebo Comparator: Vehicle Lotion - Administered to scalp and hair for 10 minutes application.


Treatment: drugs: Abametapir Lotion 0.74% w/w
200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.

Treatment: drugs: Vehicle Lotion
control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of hatched eggs pre treatment relative to proportion of hatched eggs post treatment for the abametapir and vehicle treated eggs following 14 day incubation.</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Healthy male or female based on medical history

          2. Six months of age or older.

          3. Has an active head lice infestation with a minimum of 3 live head lice and at least 10
             undamaged and unhatched head lice eggs in their hair.

          4. Agrees to an examination for head lice and compliance with the study procedures.

          5. All adult subjects must sign a written voluntary informed consent. For minors, the
             parent/ legal guardian agrees to the subject participating in the study as determined
             by the signing of an assent of informed consent.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Has scalp disease or a history of allergies or prior reactions to any head lice
             products.

          2. Has a condition that, in the opinion of the Investigator, may interfere with the
             study.

          3. Is receiving systemic or topical medication, which in the opinion of the Investigator,
             may compromise the integrity of the safety and/or efficacy assessments.

          4. Had treatment (over-the-counter (OTC) or home remedy medication) for head lice within
             14 days prior to Day 0.

          5. Has received an investigational agent within 30 days prior to Day 0.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>National Head Lice Treatment Centre - Ringwood East</hospital>
    <postcode>3135 - Ringwood East</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hatchtech Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate ovicidal efficacy of a single application of
      abametapir lotion 0.74% w/w intended for the treatment of head lice.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02097485</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>